Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company ...

One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from ...

Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking ...

However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...